Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

Fig. 3

Upper panel: CD25 and HLA-DR activation marker expression in CD8+ and CD4+ T cells after stimulation of T-lymphocytes exposed to solitomab vs control BiTE®. A significant increase in CD25 and HLA-DR activation marker expression was consistently detected in both CD8+ or CD4+ T cells (CD8/CD25, CTRL VS BITE, p = 0.00000110594; CD8/HLADR, CTRL VS BITE p = 0.00017812290; CD4/CD25, CTRL VS BITE p = 0.00001948657; CD4/HLADR, CTRL VS BITE p = 0.00000732741). Lower panel: representative flow cytometry graphic evidencing the increase in the activation marker CD25 in CD8+ T lymphocytes after stimulation with Solitumab vs control BITE

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us